Tibotec News
 17 June 2009 - Unique Collaboration Between TB Alliance and Tibotec to Accelerate Tuberculosis Drug Development
Collaboration will focus on the development of TMC207 and the discovery of new drugs to treat tuberculosis
Read more...
03 June 2009 - Data on Investigational Drug TMC207 For Treatment of MDR-Tuberculosis, Published in the New England Journal of Medicine
Clinical Activity Of TMC207 shows ATP-Synthase is a Viable Target for treatment of TB
Read more...
24 April 2009 - New Data on Tibotec Investigational Hepatitic C Compounds being Presented at EASL
Tibotec antivirals take new approach to treating HCV
Read more...
05 March 2009 - HIV Experts Propose New Approach to Eradicate HIV in Latest Issue of Science
Tibotec joins other leaders from academia, industry and government in collaboration to fight HIV
Read more...
03 February 2009 - Once-Daily PREZISTA® (darunavir) For Treatment-Naïve Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy
PREZISTA Now Indicated for Adults Living with HIV at All Phases of Treatment
Read more...
15 December 2008 - Recruitment Ongoing in Europe for Two Tibotec Phase III Clinical Trials Studying TMC278 in Treatment-Naïve HIV-Infected Adults
Once-daily TMC278 is the third anti-HIV compound to be developed in Tibotec virology portfolio
Read more...
05 December 2008 - PREZISTA® (darunavir) Receives Expanded Marketing Authorisation in the European Union for Treatment-Experienced Adults with HIV-1
PREZISTA now indicated for the broad range of treatment-experienced patients in the 27 EU member states
Read more...
03 December 2008 - Tibotec and Emcure Collaborate
On Access to Darunavir for India
Read more...
27 November 2008 - European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA® (darunavir)
Part of Combination Therapy for Treatment-Naïve Adults with HIV-1
Read more...
12 November 2008 - Tibotec Data Presented at ICAAC and HIV9 Follow Key Regulatory Approvals for Anti-HIV Compounds
New findings from ARTEMIS and TITAN studies demonstrate growth of the Tibotec virology franchise
Read more...
|
